Hereditary Deafness Market: Current Analysis and Forecast (2023-2030)

Hereditary deafness refers to hearing loss that is passed down through generations within a family due to genetic factors. It can be caused by mutations in various genes involved in the development or function of the auditory system. Depending on the specific genetic mutation, hereditary deafness can be present at birth or develop later in life. Innovations in treatment options, which may include hearing aids and cochlear implants are leading to the growth of the market. Several other factors, such as rising research & development activities, rising healthcare expenditure, rising regulatory support, and a surge in government collaborations & partnerships are leading drivers of hereditary deafness globally.

The Hereditary Deafness Market is expected to grow at a steady rate of around 5.1% owing to the rising therapeutic developments for treating deafness. For instance, in January 2024, a research conducted in Fudan, China with Harvard Medical School researchers treated six children between the ages of one to seven suffering from a type of inherited deafness through gene therapy, in which five of the six children showed signs of improved hearing. Several factors, including a surge in the incidence of hearing loss, increasing awareness regarding hereditary deafness, and increased investments in otolaryngology departments are driving the market's growth during the forecast period. Apart from this, accelerated treatment efficiency with hereditary deafness has resulted in effective treatment procedures which are also driving this market of hereditary deafness at a steady rate.

Based on the diagnosis type, the market is segmented into physical examination, molecular genetic testing, and others. The physical examination segment held the maximum share in the global market of hereditary deafness in 2022 owing to the rising demand for hereditary deafness diagnostics. Physical examinations are essential for identifying external ear anomalies, middle ear pathologies, and other structural abnormalities that may contribute to hereditary deafness. Additionally, physical examinations can help assess overall health status, identify syndromic features associated with certain genetic mutations, and guide further diagnostic investigations. Thus, among the diagnosis types, the physical examination segment held a significant market share in 2022.

Based on treatment type, the market is categorized into hearing aids, cochlear implants, and others. The cochlear implants segment is expected to hold a significant share of the market in the forecast period owing to the rising product innovations and approvals. For instance, in December 2023, Advanced Bionics, a provider of cochlear implant technology, received FDA approval and announced the expansion of its cochlear implant sound processor product, Marvel CI, and feature offerings to improve hearing care delivery and patient outcomes. Cochlear implants are electronic devices that can provide a sense of sound to individuals with severe to profound hearing loss who do not benefit from hearing aids. They consist of an external processor worn behind the ear and an internal component surgically implanted under the skin. Cochlear implants can significantly improve speech perception and communication abilities in many people with severe hearing loss. Thus, the cochlear implants category is expected to witness a higher CAGR amongst treatment types during the forecast period.

For a better understanding of the market adoption of hereditary deafness, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the surge in cases of hereditary deafness, rising awareness about hereditary deafness, and the rising number of investments in introducing innovative otolaryngology therapies. For instance, according to the U.S. Department of Health and Human Services, about 2 to 3 out of every 1,000 children in the U.S. are born with a detectable level of hearing loss in one or both ears. Government organizations are initiating hereditary deafness awareness programs for the sake of the growing deafness cases in the region. Thus, amongst regions, North America held a significant share of the market in 2022.

Some of the major players operating in the market include Cochlear Ltd; Envoy Medical; Advanced Bionics AG and affiliates; Zhejiang Nuoerkang Neuroelectronics Technology Co., Ltd.; Oticon Medical A/S; Medtronic; Sonova; Audina Hearing Instruments, Inc.; RION Co., Ltd.; GN Store Nord A/S.